Get a free sample of Carboprost Tromethamine Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Carboprost Tromethamine Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Carboprost Tromethamine Market Size
Carboprost Tromethamine Market size was valued at USD 1.5 billion in 2023 and is estimated to grow at a CAGR of 7.9% between 2024 and 2032. Carboprost tromethamine is a synthetic prostaglandin analogue medication, along with other abortion drugs, which estimated to reach USD 49.3 billion by 2032, are used in obstetrics and gynecology for various purposes including the induction of abortion, termination of pregnancy, treatment of postpartum, and management of uterine atony.
The increasing prevalence of postpartum hemorrhage has emerged as a significant driver for the market. For instance, according to the World Health Organization (WHO) in 2023, approximately 14 million women experienced postpartum hemorrhage, leading to approximately 70,000 maternal deaths globally. Therefore, integrating postpartum health supplements into comprehensive care strategies can further enhance maternal recovery and mitigate the risks associated with postpartum hemorrhage, addressing a critical healthcare challenge.
Furthermore, increasing initiatives by government and various organizations, rising publicly funded family planning services, among other contributing factors are estimated to propel the growth.
Why is the demand for carboprost tromethamine from hospital pharmacies increasing?
The hospital pharmacies segment is estimated to account for USD 1.8 billion by 2032, backed by stringent quality control standards to ensure the safety and efficacy of medications.
What is the size of carboprost tromethamine industry?
The global carboprost tromethamine market was valued at USD 1.5 billion in 2023 and is estimated to record a CAGR of 7.9% between 2024 and 2032, driven by the increasing prevalence of postpartum hemorrhage.
How big is North America carboprost tromethamine industry?
North America carboprost tromethamine market accounted for USD 613.5 million in 2023 and will continue to grow through 2032, favored by the well-developed healthcare infrastructure with state-of-the-art facilities and advanced medical technologies.
Who are the key players involved in carboprost tromethamine industry?
Advancion Corporation, Amneal Pharmaceuticals, Inc., Apionex Pharma Pvt Ltd., Biosynth Limited, Bio-Techne Corporation, BioSpectra Inc., Dr. Reddy's Laboratories Ltd, Merck & Co., Inc., Monvi Laboratories Private Limited, and Woodward, Inc. among others.